Demonstrates reduced shrinkage in isotactic polypropylene using an anti-nucleating agent, suggesting improved dimensional stability.
The high shrinkage of isotactic polypropylene (iPP) during molding limits its application in high-precision products. Although nucleating agents are commonly used to regulate crystallization, they frequently increase shrinkage. In this study, l-isoleucine (l-Ile), an anti-nucleating agent that inhibits crystallization, was incorporated into iPP to regulate shrinkage behavior, with the nucleating agent HPN-68L used for comparison. Shrinkage tests show that l-Ile reduces iPP shrinkage by 11.8% in the flow direction and 14.2% in the transverse direction, whereas HPN-68L increases shrinkage by 15.4% and 27%, respectively. Crystallization behavior was analyzed by using differential scanning calorimetry (DSC), flash differential scanning calorimetry (Flash DSC), polarized optical microscopy (POM), and X-ray diffraction (XRD). Results indicate that l-Ile suppresses nucleation and decreases the crystallinity, while HPN-68L exhibits the opposite effect. The shrinkage-reducing mechanism of l-Ile is attributed to its ability to reduce the crystallinity of iPP, thereby increasing the proportion of the amorphous polymer characterized by a high free volume. Moreover, the relationship between crystallinity and ultrafast cooling rates was established using Flash DSC, providing process optimization guidance for the production of low-shrinkage iPP products. This study presents not only a novel strategy for low-shrinkage modification of iPP but also new insights into enhancing the dimensional stability of semicrystalline polymers.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: